Delayed Nasdaq 11:06:05 2024-04-23 am EDT 5-day change 1st Jan Change
1.931 USD +1.12% Intraday chart for InspireMD, Inc. -13.63% -30.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M MT
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InspireMD Gets CE Mark Recertification From the European Union MT
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America CI
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions CI
Transcript : InspireMD, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M MT
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption Clinical Trial CI
InspireMD, Inc. Supports CMS? Final National Coverage Determination Expanding Coverage of Carotid Stenting to Include Both Asymptomatic and Standard Risk Patients CI
InspireMD, Inc. Announces Management Changes CI
InspireMD Promotes Shane Gleason to Chief Commercial Officer MT
InspireMD, Inc. Announces Management Appointments CI
Transcript : InspireMD, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (NSPR) INSPIREMD Reports Q2 Revenue $1.6M MT
InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial CI
Piper Sandler Initiates InspireMD at Overweight With $3 Price Target MT
Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating MT
Insider Buy: Inspiremd MT
Insider Buy: Inspiremd MT
Insider Buy: Inspiremd MT
Insider Buy: Inspiremd MT
Transcript : InspireMD, Inc., Q1 2023 Earnings Call, May 16, 2023
Chart InspireMD, Inc.
More charts
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.91 USD
Average target price
4.5 USD
Spread / Average Target
+135.60%
Consensus
  1. Stock Market
  2. Equities
  3. NSPR Stock
  4. News InspireMD, Inc.
  5. InspireMD, NAMSA Enter Into Outsourcing Partnership